Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient’s own resident stem cells. The company’s programs aim to repair neurological function lost due to disease or injury. The company’s extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury and multiple sclerosis.

Stem cell research continues to push the boundaries of science offering glimpses on how an organism develops from a single cell and how it repairs and replaces damaged cells at maturity. Although Aegera's main focus is currently on cancer therapeutics, we have a continued interest in exploring the unlimited potential of cell based therapies through partnerships and collaborations, supported through externally generated funds.

Celmed is developing breakthrough products to treat cancer. The Company applies rational drug design and pharmacogenomic concepts to improve cancer patient care, an approach that offers significant potential both in terms of efficacy and safety to the patient. Celmed’s two lead products, Theralux™ and NB1011, are currently in Phase I/II clinical development. Theralux™, a photodynamic-based therapy, is being evaluated in three therapeutic areas: the prevention of graft-versus-host disease (GvHD), the treatment of autoimmune diseases and the purge of cancerous cells from blood stem cell transplants.

PharmaGap Inc. is a biotechnology company with a core focus discovering and developing novel therapeutic drugs for the treatment of cancer. Founded in 1999, the Company is a spin-off out of Canada’s pre-eminent biological research organization, the National Research Council (NRC). PharmaGap’s unique research and drug development platform is a result of almost 10 years and $10 million of funded research by NRC scientists.

StemCell Technologies is committed to supporting stem cell and many other areas of life science research worldwide by providing enabling research tools that are innovative, timely and of consistently high quality.

Transition Therapeutics Inc. is a publicly traded biopharmaceutical company developing novel approaches and therapeutics for the treatment of diabetes, multiple sclerosis (MS), hepatitis C, Alzheimer's disease, and restenosis.Islet neogenesis is the process by which islet cells are formed from stem cells in the pancreatic duct during fetal development.